Why the study?
Coronary atherosclerosis and recurrent cardiovascular events are common in type 2 myocardial infarction, but cardiovascular resource utilization among these patients is unclear.
Does cardiovascular resource utilization differ between patients with type 2 myocardial infarction compared to type 1 myocardial infarction?
Does cardiovascular resource utilization differ between patients with type 2 myocardial infarction compared to type 1 myocardial infarction?
Answers are grounded in this paper and cite their sources.
Patients with type 2 myocardial infarction receive significantly less cardiovascular testing and secondary preventative therapies compared to those with type 1 myocardial infarction in the United States.
BACKGROUND: Coronary atherosclerosis and recurrent cardiovascular events are common among individuals with type 2 myocardial infarction (T2MI). However, cardiovascular resource utilization among T2MI patients is unclear. OBJECTIVES: The aim of the study was to characterize cardiovascular resource utilization among T2MI patients across the United States. METHODS: Using Optum's de-identified Clinformatics Data Mart Database, cardiovascular procedures, physician services, and prescriptions within 6 months postdischarge were compared among patients with T2MI vs type 1 myocardial infarction (T1MI) between October 1, 2017, and June 30, 2020. Multivariable logistic regression examined the odds of resource utilization in T2MI vs T1MI and identified predictors of utilization for T2MI. RESULTS: inhibitors (4.8% [603/14,176] vs 52.8% [44,833/99,593], adjusted OR: 0.28; 95% CI: 0.25-0.31), beta blockers (27.1% [2,070/14,176] vs 62.8% [38,219/99,593], OR: 0.59; 95% CI: 0.55-0.63), statins (19.1% [1,439/14,176] vs 59.1% [32,434/99,593], OR: 0.51; 95% CI: 0.47-0.55), and SGLT2i or glucagon-like peptide-1 agonists (4.8% [595/14,176] vs 35.4% [30,202/99,593], OR: 0.30; 95% CI: 0.27-0.33) as compared to T1MI. Patients with T2MI were significantly less likely to undergo an echocardiogram (71.8% [10,179/14,176] vs 82.9% [82,551/99,593], OR: 0.61; 95% CI: 0.58-0.64) and coronary angiogram (11.7% [1,664/14,176] vs 76.6% [76,327/99,593], OR: 0.10; 95% CI: 0.09-0.11) compared to T1MI. CONCLUSIONS: In the United States, T2MI patients received less cardiovascular testing and secondary preventative therapies than T1MI patients.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: